title: Diversity of killer cell immunoglobulin-like receptor (KIR) genotypes and KIR2DL2/3 variants in HCV treatment outcome.
abstract: The aim of this study was to analyse the distribution of KIR haplotypes and the KIR2DL2/3 alleles in chronic HCV-infected patients in order to establish the influence on the response to pegylated interferon plus ribavirin classical treatment. The alleles study of previously associated KIR2DL2/3 showed that KIR2DL2*001 was more frequent in non-SVR (NSVR) (42.2% vs. 27.5%, p<0.05) and KIR2DL3*001 was associated with sustained viral response (SVR) (41.6% vs. 61.2%, p<0.005). The KIR2DL3*001-HLA-C1 association was also significant (24.5% vs. 45.7%, p<0.001). From the frequencies of KIR obtained, 35 genotypes were assigned on the basis of previous studies. The centromeric A/A genotype was more frequent in SVR (44.1% vs. 34.5%, p<0.005) and the centromeric B/B genotype was found to be significantly more frequent in NSVR (20.9% vs. 11.2%, p<0.001). The logic regression model showed the importance of KIR genes in predicting the response to combined treatment, since the positive predictive value (PPV) was improved (from 55.9% to 75.3%) when the analysis of KIR was included in addition to the IFNL3 rs12979860 polymorphism. The study of KIR receptors may be a powerful tool for predicting the combined treatment response in patients with chronic HCV infection in association with the determination of IFNL3 polymorphism.
authors.affiliation: Immunology Service, Hospital Universitario Central de Asturias, Oviedo, Spain.
authors.forename: Jose Ramón
authors.initials: JR
authors.lastname: Vidal-Castiñeira
authors.affiliation: Immunology Service, Hospital Universitario Central de Asturias, Oviedo, Spain.
authors.forename: Antonio
authors.initials: A
authors.lastname: López-Vázquez
authors.affiliation: Immunology Service, Hospital Universitario Central de Asturias, Oviedo, Spain.
authors.forename: Jesús
authors.initials: J
authors.lastname: Martínez-Borra
authors.affiliation: Oficina de Investigación Biosanitaria (OIB), Oviedo, Spain.
authors.forename: Pablo
authors.initials: P
authors.lastname: Martínez-Camblor
authors.affiliation: Liver Unit and Division of Hepatology and Gene Therapy, Clínica Universitaria de Navarra, University of Navarra, Pamplona, Spain.
authors.forename: Jesús
authors.initials: J
authors.lastname: Prieto
authors.affiliation: Liver Unit, Gastroenterology Service, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP), Universidad Autónoma de Madrid and CIBERehd, Instituto de Salud Carlos III, Madrid, Spain.
authors.forename: Rosario
authors.initials: R
authors.lastname: López-Rodríguez
authors.affiliation: Liver Unit, Gastroenterology Service, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP), Universidad Autónoma de Madrid and CIBERehd, Instituto de Salud Carlos III, Madrid, Spain.
authors.forename: Paloma
authors.initials: P
authors.lastname: Sanz-Cameno
authors.affiliation: Gastroenterology Service, Hospital San Agustín, Avilés, Spain.
authors.forename: Juan
authors.initials: J
authors.lastname: de la Vega
authors.affiliation: Gastroenterology Service, Hospital Universitario Central de Asturias, Oviedo, Spain.
authors.forename: Luis
authors.initials: L
authors.lastname: Rodrigo
authors.affiliation: Gastroenterology Service, Hospital Universitario Central de Asturias, Oviedo, Spain.
authors.forename: Rosa
authors.initials: R
authors.lastname: Pérez-López
authors.affiliation: Gastroenterology Service, Hospital Universitario Central de Asturias, Oviedo, Spain.
authors.forename: Ramón
authors.initials: R
authors.lastname: Pérez-Álvarez
authors.affiliation: Immunology Service, Hospital Universitario Central de Asturias, Oviedo, Spain; Fundación Renal Iñigo Álvarez de Toledo, Madrid, Spain.
authors.forename: Carlos
authors.initials: C
authors.lastname: López-Larrea
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005838:Genotype; D006239:Haplotypes; D016174:Hepacivirus / Q000187:drug effects; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000235:genetics / Q000821:virology; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D007372:Interferons; D007378:Interleukins / Q000235:genetics; D007694:Killer Cells, Natural / Q000276:immunology; D016015:Logistic Models; D020641:Polymorphism, Single Nucleotide; D054343:Receptors, KIR2DL2 / Q000235:genetics*; D054344:Receptors, KIR2DL3 / Q000235:genetics*; D012254:Ribavirin / Q000627:therapeutic use*; D016896:Treatment Outcome; D000095022:Interferon Lambda
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D007372:Interferons; D007378:Interleukins; D054343:Receptors, KIR2DL2; D054344:Receptors, KIR2DL3; D012254:Ribavirin; C000624353:interferon-lambda, human; D000095022:Interferon Lambda; C515077:KIR2DL2 protein, human; C515078:KIR2DL3 protein, human